Stock Scorecard



Stock Summary for Pfizer Inc (PFE) - $25.14 as of 8/18/2025 11:14:03 AM EST

Total Score

14 out of 30

Safety Score

63 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for PFE

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PFE

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PFE

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PFE

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PFE (63 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 6
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 8
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 9
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for PFE

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis ( FAP ) 8/18/2025 12:30:00 PM
These 3 Dividend Stocks Have Yields Above 5%, Plus They Raise Their Payouts Every Year 8/18/2025 9:23:00 AM
Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older 8/18/2025 5:00:00 AM
Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older 8/18/2025 5:00:00 AM
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA 8/17/2025 11:30:00 PM
2 Top Dividend Stocks to Buy on the Dip 8/16/2025 1:07:00 PM
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet. 8/16/2025 12:45:00 PM
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease - Pfizer ( NYSE:PFE ) 8/15/2025 7:35:00 PM
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs 8/15/2025 2:00:00 PM
After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again? 8/15/2025 11:15:00 AM

Financial Details for PFE

Company Overview

Ticker PFE
Company Name Pfizer Inc
Country USA
Description Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2025
Next Earnings Date 11/4/2025

Stock Price History

Last Day Price 25.14
Price 4 Years Ago 48.90
Last Day Price Updated 8/18/2025 11:14:03 AM EST
Last Day Volume 31,844,848
Average Daily Volume 43,576,205
52-Week High 28.43
52-Week Low 20.18
Last Price to 52 Week Low 24.58%

Valuation Measures

Trailing PE 13.30
Industry PE 43.35
Sector PE 59.06
5-Year Average PE 10.78
Free Cash Flow Ratio 86.69
Industry Free Cash Flow Ratio 15.81
Sector Free Cash Flow Ratio 30.26
Current Ratio Most Recent Quarter 1.16
Total Cash Per Share 0.29
Book Value Per Share Most Recent Quarter 15.60
Price to Book Ratio 1.61
Industry Price to Book Ratio 31.11
Sector Price to Book Ratio 26.93
Price to Sales Ratio Twelve Trailing Months 2.24
Industry Price to Sales Ratio Twelve Trailing Months 34.46
Sector Price to Sales Ratio Twelve Trailing Months 15.21
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 5,685,550,000
Market Capitalization 142,934,727,000
Institutional Ownership 67.46%

Dividends

Ex-Dividend Date 7/25/2025
Previous Dividend Amount 0.4300
Current Dividend Amount 0.4300
Total Years Dividend Increasing Dividend Contender - Increasing for 14 Years
Trailing Annual Dividend Rate 1.71
Trailing Annual Dividend Yield 6.81%
Forward Annual Dividend Rate 1.72
Forward Annual Dividend Yield 6.85%
5-Year Dividend Payments Count 20
3-Year Average Dividend Yield 6.67%
5-Year Average Dividend Yield 4.97%
1-Year Dividend Growth Rate Percentage 2.38%
3-Year Dividend Growth Rate Percentage 1.18%
5-Year Dividend Growth Rate Percentage 2.47%
All-Time Dividend Growth Rate Percentage 8.79%
Dividend Payout Ratio 90.48%

Income Statement

Quarterly Earnings Growth YOY 6,974.00%
Annual Earnings Growth 276.00%
Reported EPS 12 Trailing Months 1.89
Reported EPS Past Year 1.70
Reported EPS Prior Year 3.11
Net Income Twelve Trailing Months 10,728,000,000
Net Income Past Year 8,020,000,000
Net Income Prior Year 2,133,000,000
Quarterly Revenue Growth YOY 10.30%
5-Year Revenue Growth 9.10%
Operating Margin Twelve Trailing Months 28.70%

Balance Sheet

Total Cash Most Recent Quarter 1,638,000,000
Total Cash Past Year 1,043,000,000
Total Cash Prior Year 2,853,000,000
Net Cash Position Most Recent Quarter -54,992,000,000
Net Cash Position Past Year -55,660,000,000
Long Term Debt Past Year 56,703,000,000
Long Term Debt Prior Year 60,499,000,000
Total Debt Most Recent Quarter 56,630,000,000
Equity to Debt Ratio Past Year 0.61
Equity to Debt Ratio Most Recent Quarter 0.61
Total Stockholder Equity Past Year 88,203,000,000
Total Stockholder Equity Prior Year 89,014,000,000
Total Stockholder Equity Most Recent Quarter 88,695,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 12,438,000,000
Free Cash Flow Per Share Twelve Trailing Months 2.19
Free Cash Flow Past Year 9,835,000,000
Free Cash Flow Prior Year 4,793,000,000

Options

Put/Call Ratio 0.37
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.13
MACD Signal 0.06
20-Day Bollinger Lower Band 20.93
20-Day Bollinger Middle Band 23.35
20-Day Bollinger Upper Band 25.77
Beta 0.44
RSI 59.79
50-Day SMA 24.71
150-Day SMA 28.98
200-Day SMA 32.33

System

Modified 8/16/2025 7:34:12 AM EST